Trial Profile
A 28-week Multicenter, Randomized, Double-masked, Placebo Controlled, Dose-ranging Phase III Study to Assess AIN457 Versus Placebo in Inducing and Maintaining Uveitis Suppression in Adults With Active, Non-infectious, Intermediate, Posterior or Panuveitis Requiring Immunosuppression (INSURE Study)
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 28 Jul 2020
Price :
$35
*
At a glance
- Drugs Secukinumab (Primary)
- Indications Intermediate uveitis; Panuveitis; Posterior uveitis
- Focus Registrational; Therapeutic Use
- Acronyms INSURE
- Sponsors Novartis
- 27 Jul 2020 This trial is completed in UK(Global End Date: 27 Oct 2010), according to European Clinical Trials Database record.
- 18 Dec 2014 New trial record